Drugs For Neglected Diseases Initiative (Dndi)
Genf, GE
- UEI
- J5KKXTB86PL6
- CAGE
- SEN44
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- International Organization
- SAM.gov registration date
- Physical address
- Chemin Camille-Vidart 15, 1202 Genf, Switzerland
- Website
- dndi.org
- Founded
- 2003
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| K777 for treatment of chagas disease: IND-enabling studies and IND submission | National Institutes of Health | $1,243,674 | |
| Development of a low cost formulation of amphotericin b | National Institutes of Health | $1,086,078 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Sloan-Kettering Institute For Cancer Research | U19AI171399 | $36,102 |
Quick answers
Is Drugs For Neglected Diseases Initiative (Dndi) registered in SAM.gov?
Yes. Drugs For Neglected Diseases Initiative (Dndi)'s SAM.gov registration is active through April 30, 2027.
What is Drugs For Neglected Diseases Initiative (Dndi)'s most recent federal award?
Drugs For Neglected Diseases Initiative (Dndi)'s most recent federal grant award is K777 for treatment of chagas disease: IND-enabling studies and IND submission (R01AI090592), from National Institutes of Health, on September 22, 2010.
On GovTribe
See Drugs For Neglected Diseases Initiative (Dndi)'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors